- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02903823
Intrathecal (IT) Baclofen Drug Distribution (ITB)
Intrathecal (IT) Baclofen Drug Distribution Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
While ITB therapy is commonly recommended for treatment of severe spasticity due to a variety of diseases, the location of optimal drug (baclofen) delivery has not been defined in a controlled study. Furthermore, the cost of pharmacological management in these patients is significant, and optimal location for drug delivery through an implantable drug pump may have significant impact on the cost burden of maintenance refills. It is the goal of this pilot study to determine whether there is a significant therapeutic advantage to place the ITB catheter within the cervical, thoracic or lumbar region of the spine. It is also a goal of this pilot study to determine whether the origin of spasticity influences the effect of Lioresal Intrathecal (baclofen injection) on ITB catheters located in the cervical, thoracic or lumbar regions of the spine. The investigators propose to study the impact of catheter location on the reduction in spasticity within a group of patients who are scheduled for ITB trial. In studying the impact of catheter location among patients with spinal versus cerebral origin of spasticity, the disease origin may also have a significant impact on baclofen dosing relative to the placement of the catheter.
In addition, the pharmacokinetic half-life and the variability of intrathecal baclofen is poorly understood as data is limited. In order to provide initial data regarding CSF baclofen washout, samples of spinal fluid obtained just prior to- and following IT baclofen administration will be obtained for delayed analysis. The results of these pharmacological analysis may refine the understanding of how quickly baclofen is distributed from a given catheter location, and whether it is affected by catheter location or disease origin. Since multiple catheter locations will be studied within a given patient, it also affords the opportunity to sample small amounts of CSF at key anatomical sites along the spinal axis as a secondary objective.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients with spasticity from spinal origin (spinal cord injury)
- Adult patients with spasticity of cerebral origin (cerebral palsy and cerebrovascular accident)
- Adult women of child bearing age with a negative pregnancy test
Exclusion Criteria:
- Patients with spasticity from Multiple sclerosis
- Pregnant women
- Patients under the age of 18 years
- Patients over the age of 50
- Patients who are unable to have an MRI scan of the total spine
- Patients with spinal deformity that would prevent easy access to the lumbar intrathecal space
- Patients who have an allergic reaction to IT baclofen
- Patients who have significant headache from CSF withdrawal
- Patients who have intradural blockage that prevents advancing the IT catheter to the level of C4
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Baclofen injection at designated spinal level
Days 2,3,4,5 a baclofen injection bolus will be given in the catheter, located at C4, T4, T10 and L2 respectively.
Effect of baclofen injection (50 microgram bolus) upon rigidity will be assessed manually using the Modified Ashworth rating score for selected upper and lower extremities.
|
A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location.
The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Cerebral Origin
Time Frame: Baseline to 6 hours post-injection
|
The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: "0, 1, 1.5, 2, 3, or 4") used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested. This outcome looks at subjects with spasticity of cerebral origin. |
Baseline to 6 hours post-injection
|
Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Spinal Origin
Time Frame: Baseline to 6 hours post-injection
|
The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: "0, 1, 1.5, 2, 3, or 4") used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested. This outcome looks at subjects with spasticity of spinal origin. |
Baseline to 6 hours post-injection
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Penn RD. Catheter implant systems for intrathecal drug delivery. J Neurosurg. 1996 Apr;84(4):713. doi: 10.3171/jns.1996.84.4.0713a. No abstract available.
- Kroin JS, Ali A, York M, Penn RD. The distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery. 1993 Aug;33(2):226-30; discussion 230.
- Grabb PA, Guin-Renfroe S, Meythaler JM. Midthoracic catheter tip placement for intrathecal baclofen administration in children with quadriparetic spasticity. Neurosurgery. 1999 Oct;45(4):833-6; discussion 836-7. doi: 10.1097/00006123-199910000-00020.
- Albright AL. Technique for insertion of intraventricular baclofen catheters. J Neurosurg Pediatr. 2011 Oct;8(4):394-5. doi: 10.3171/2011.7.PEDS11211.
- Coffey JR, Cahill D, Steers W, Park TS, Ordia J, Meythaler J, Herman R, Shetter AG, Levy R, Gill B, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg. 1993 Feb;78(2):226-32. doi: 10.3171/jns.1993.78.2.0226.
- Albright AL, Turner M, Pattisapu JV. Best-practice surgical techniques for intrathecal baclofen therapy. J Neurosurg. 2006 Apr;104(4 Suppl):233-9. doi: 10.3171/ped.2006.104.4.233.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Manifestations
- Muscle Hypertonia
- Muscle Spasticity
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- GABA Agents
- Neuromuscular Agents
- Muscle Relaxants, Central
- GABA Agonists
- GABA-B Receptor Agonists
- Baclofen
Other Study ID Numbers
- 151399
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscle Spasticity
-
Fondation Ophtalmologique Adolphe de RothschildNot yet recruitingSpasticity, Muscle
-
Vancouver Island Health AuthorityRecruiting
-
Universitatea de Medicina si Farmacie Iuliu HatieganuRecruiting
-
Nantes University HospitalCompiègne University of TechnologyCompleted
-
University of AlbertaRecruiting
-
Rigshospitalet, DenmarkEnrolling by invitation
-
University of MalagaUnknownSpasticity, Muscle
-
Sultan Abdulhamid Han Training and Research Hospital...CompletedSpasticity, MuscleTurkey
-
Medy-ToxCompletedSpasticity, Muscle
-
Shirley Ryan AbilityLabSuspended
Clinical Trials on Baclofen bolus injection
-
Institut GuttmannMedtronicCompletedNeuropathic PainSpain
-
Korea University Guro HospitalHana Pharm. Co., LtdCompletedAnesthesia, General | AdultKorea, Republic of
-
Piramal Critical Care, Ltd.CompletedSevere SpasticityUnited States
-
Tanta UniversityUnknownLiver Cirrhosis | Muscle CrampsEgypt
-
Radboud University Medical CenterCompletedShock | Septic | SevereNetherlands
-
AC Camargo Cancer CenterCompletedBreast Cancer | RadiodermatitisBrazil
-
Samsung Changwon HospitalUnknownPeptic Ulcer | Peptic Ulcer Hemorrhage | Peptic Ulcer, Acute With Hemorrhage | Proton Pump Inhibitor OverdoseKorea, Republic of
-
Rob RutledgeNova Scotia Health AuthorityCompletedBreast CancerCanada
-
Tulane UniversityWithdrawnRadiotherapyUnited States
-
Providence University, TaiwanUnknown